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Introduction: Vaccination against amyloid-β protein (Aβ42) induces high levels of antibody, making it a promising
strategy for treating Alzheimer’s disease (AD). One drawback in the past was that clinical trial approval was withheld
because of speculation that the Aβ42 vaccine induces CD4+ T cell infiltrations into the central nervous system. To
reduce T-cell activation while concomitantly maintaining high anti-Aβ42 titers is a great challenge in immunology.
Methods: We aimed to demonstrate that coimmunization with Aβ42 protein and expression plasmid can be
beneficial in a mouse AD model and can prevent inflammation. We immunized the AD mice with the
coimmunization vaccine and assessed behavior change and Aβ42 deposition. Furthermore, to determine the safety
of the coimmunization vaccine, we used an induced Aβ42-EAE model to mimic the meningoencephalitis that
happened in the AN-1792 vaccine clinical phase II trial and tested whether the coimmunization vaccine could
ameliorate T-cell-mediated brain inflammation.
Results: The coimmunization vaccination reduced Aβ plaques and significantly ameliorated cognitive deficit while
inhibiting T-cell-mediated brain inflammation and infiltration. These studies demonstrate that the coimmunization
strategy that we describe in this article can ameliorate AD pathology without notable adverse effects in mice.
Conclusions: A coimmunization strategy leading to the development of a safe immunotherapeutic/preventive
protocol against AD in humans is warranted.Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease
characterized by progressive cognitive dysfunction, massive
loss of neurons and deposition of amyloid plaques and
neurofibrillary tangles [1]. The pathological accumulation
of amyloid is possibly due to site-specific abnormal process-
ing of amyloid precursor protein (APP). Investigators in
previous studies have shown that deposition of amyloid-β
protein (Aβ), particularly the Aβ40 and Aβ42 forms, in
amyloid plaques is one of the hallmarks of the disease [2-4]
and could trigger a T-cell-mediated (auto)immune reactions
[5]. A large body of evidence supports the amyloid cascade
hypothesis, which states that accumulation of Aβ is the* Correspondence: bwang3@fudan.edu.cn
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stated.initiating step for the onset of AD. Therefore, most research
has centered on Aβ, and many Aβ-related therapeutic
strategies have been proposed and/or developed, includ-
ing immunotherapy [6-9].
After successful experiments in AD model mice [8],
researchers in a phase IIa immunotherapy trial in patients
with mild to moderate AD showed that about 20% of vacci-
nees had immunoglobulin G (IgG) responses. However, the
trial had to be stopped because 6% of the vaccinated pa-
tients developed meningoencephalitis [10]. Pathology re-
ports indicated that the cases of meningoencephalitis were
severe, which suggested that vaccine-induced T-cell infiltra-
tion might be the cause [11]. This raised a critical question
about how to develop a vaccine that can elicit a high level
of antibody against Aβ42 antigen while preventing T-cell
responses [12-16]. Several approaches to answering
this question have been employed, including the use of
truncated versions of Aβ42 that exclude T-cell epitopestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Wang et al. Alzheimer's Research & Therapy 2014, 6:26 Page 2 of 17
http://alzres.com/content/6/3/26(for example, Aβ1–28, Aβ1–16, Aβ1–14 and Aβ1–9).
In many of the previously reported Aβ immunization
studies, researchers have found reduced cerebral Aβ levels
and/or improved cognition in mice, nonhuman primates
and humans [15,17-21]. Monoclonal antibodies against
Aβ42 have been used in passive vaccination [22-25],
including bapineuzumab, solanezumab and ponezumab
[26-28]. Although selecting the B-cell epitopes for vac-
cines could avoid the T-cell response, short peptides do
not have the same strong ability to stimulate a high titer
of IgG and would therefore need to be modified, adding
to the production cost and complexity of vaccine studies
in AD [29]. Passive immunization with an antibody may
not stimulate the unwanted T-cell response, but anti-
bodies are more expensive than protein or DNA vaccines
and do not last very long in vivo. The various strategies
being used for vaccine development are at different stages,
and some have a bearing on the use of DNA and protein
coimmunization or the induction of anti-inflammatory,
regulatory T cells (Tregs). Lambracht-Washington et al.
demonstrated a novel strategy of using peptide prime plus
DNA boost immunization regimens [30]. These regimens
induced higher levels of anti-Aβ42 antibody responses,
mainly of T helper type 2 (Th2) cells rather than Th1 cells,
in contrast to traditional Aβ42 peptide immunizations. Fur-
thermore, T-cell responses were lower before than after
peptide immunization. Although the protocol demon-
strated a potential alternative way to generate high levels of
antibody against Aβ plaques, T-cell responses potentially
could be autoreactivated if multiple immunizations were re-
quired. Liu et al. [29] used a diphtheria toxoid (DT)-conju-
gated Aβ1–15 vaccine that deleted the T-cell epitope and
found that it upregulated CD25+ Tregs. Whether these
regulatory T cells were specific for the Aβ peptide and had
a major anti-inflammatory impact needs to be further in-
vestigated. The results obtained with other vaccines have
indicated a capacity to induce T cells with the CD4+CD25
+Foxp3+ regulatory phenotype that is responsive to Aβ15-
DT, but not to the Aβ1–15 epitope or to intact Aβ1–40/
Aβ1–42 [29]. This finding indicates that induction of
antigen-specific regulatory T cells (iTregs), even when not
directly against an Aβ antigen, may improve the safety of
Aβ-based vaccines against inflammation.
Tregs have been shown to be important regulators of tol-
erance, which suggests the possibility of developing direct
strategies to use these cells to prevent or even to treat auto-
immune inflammation [31]. Various approaches to inducing
Treg cells to constrain autoreactive T cells have been ex-
plored. Notably, the induction of antigen-specific iTreg cells
targeted to allergy, asthma and autoimmune disease anti-
gens is considered a promising immunomodulatory strategy
[32-34]. Therefore, it may be possible to develop a strategy
to induce antigen-specific iTreg cells targeted against Aβ42
antigen without affecting the antibody response.We have previously reported that coimmunization
with a DNA vaccine and its encoded protein antigen in-
duced iTreg to inhibit antigen-specific T-cell function
in vivo. Importantly, this suppression had no effect on
antibody production [33]. In this article, we demonstrate
that coimmunization with Aβ42 protein and a DNA vac-
cine encoding Aβ42 in an AD mouse model induced high
titers of anti-Aβ42 antibodies, which resulted in clearance
of amyloid plaques and improvement in cognitive behav-
ior. Strikingly, the coimmunization also induced antigen-
specific iTreg cells that ameliorated T-cell-mediated brain
inflammation. We show that the prevention of inflamma-
tion is due, at least in part, to the suppressive effects of
iTregs on CD4+ effector T-cell (Teff) function.
Methods
Animals
Adult female C57BL/6 mice (6 to 8 weeks of age) were
purchased from the Animal Institute of the Chinese
Medical Academy (Beijing, China). APP695 mice (10-month-
old, C57BL/6 background) [35-37] were obtained from the
Chinese Academy of Medical Sciences & Comparative
Medical Center. Mice that coexpress Foxp3 and enhanced
green eGFP (Foxp3-eGFP, C57BL/6 background) were
kindly provided by Dr Minghui Zhang (Tsinghua University,
Beijing, China). APP/PS1 mice (C57BL/6 background) [38]
were kindly provided by Mathias Jucker, Hertie Institute,
Tübingen, Germany. All mouse protocols were approved
by the animal welfare committees of China Agricultural
University, Fudan University and the Institute for Age
Research. All animals were maintained under specific
pathogen-free conditions and a 12-hour light–dark cycle.
Reagents
Recombinant eukaryotic and prokaryotic plasmids were
identified by restriction enzyme digestion and verified by
sequencing analysis. The inserts were subcloned into either a
pVAX1 or pET28a vector (Invitrogen, Carlsbad, CA, USA).
Expression levels were examined by Western blot analysis
48 hours after transfection of BHK cells (American Type
Culture Collection, Manassas, VA, USA) for inserts in the
pVAX backbone or 8 hours after induction of transfected
Escherichia coli with 0.1 mM isopropyl-β-D-thiogalacto-
pyranoside for inserts in pET28 vectors.
Immunization
Female C57BL/6 mice (6 to 8 weeks old) and APP695
mice (both male and female, 10 months old) were im-
munized with various regimens via the tibialis anterior
muscle on days 0, 14, 28 and 70. These regimens were
as follows: Aβ42 protein, 200 μg/mouse; pVAX1-Aβ42,
100 μg/mouse; coimmunization, a mixture of 200 μg of
Aβ42 protein and 100 μg of pVAX1-Aβ42; a positive
control in which mice were first immunized with 200 μg
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vant (CFA; Sigma-Aldrich, St Louis, MO, USA), and
then second, third, fourth and fifth immunizations were
delivered with 200 μg of Aβ42 protein in incomplete
Freund’s adjuvant (IFA; Sigma-Aldrich).
Flow cytometry
T cells were isolated from the spleens of immunized
C57BL/6 mice or APP695 transgenic mice on day 7 after
the fourth immunization. For intracellular staining, T
cells were stimulated with Aβ42 protein at 10 μg/ml
for 8 hours and subsequently treated with brefeldin A
(BFA; BD Biosciences, San Diego, CA, USA) for 2 hours
in vitro. The cells were blocked with BD Fc Block antibody
(BD Biosciences) in phosphate-buffered saline (PBS) for 30
minutes at 4°C before being fixed with 4% paraformalde-
hyde and permeabilized with saponin (Sigma-Aldrich). The
splenocytes were intracellularly stained with the appropriate
concentrations of phycoerythrin (PE)-labeled antibodies, in-
cluding anti-Foxp3, interleukin 10 (anti-IL-10), transform-
ing growth factor β (anti-TGF-β), interferon γ (anti-IFN-γ),
anti-IL-4 and PE-cyanine 5.5 (PE-Cy5.5)-labeled anti-CD25
antibodies (eBioscience, San Diego, CA, USA) and fluor-
escein isothiocyanate (FITC)-labeled anti-CD4 antibody
(eBioscience) for 30 minutes at 4°C. The cells were washed
and analyzed with a FACSCalibur flow cytometer equipped
with CellQuest Pro software (BD Biosciences).
Immunofluorescence staining
For Aβ plaque immunohistochemistry, frozen brain sec-
tions taken from 9-month-old APP/PS1-transgenic mice
were warmed to room temperature for 30 minutes and
fixed in ice-cold acetone for 5 minutes before being air-
dried for 30 minutes. The sections were incubated with
normal serum for 30 minutes to block nonspecific bind-
ing of immunoglobulin. The tissue sections were reacted
first for 1 hour at room temperature or overnight at 4°C
with (1) antisera induced by coimmunization or by pro-
tein vaccination, or (2) with sera from untreated mice
(all sera were at 1:200 dilution) or (3) with monoclonal
antibody 3552 (1:2,000 dilution) as a positive control. All
serum dilutions were made in primary antibody dilution
buffer. After incubation, the sections were washed three
times with PBS, then incubated with Alexa Fluor 555–
labeled secondary antibody (1:1,000 dilution; Invitrogen)
for 30 minutes at room temperature and washed three
times with PBS. After brush transfer of sections onto
glass slides, plaques were detected by fluorescence mi-
croscopy (Carl Zeiss, Jena, Germany) at 546-nm emis-
sion. The nuclei were stained with 4′,6-diamidino-2-
phenylindole (DAPI), and the sections were incubated
with 1 μg/ml DAPI for 5 minutes in the dark at room
temperature, washed twice with PBS and detected at
405-nm emission.T-cell proliferative response
Single-lymphocyte suspensions were obtained from
the spleens of immunized C57BL/6 mice or APP695
mice on day 7 after the fourth immunization. Cells in
RPMI 1640/Ham’s F-10 Nutrient Mix medium (GIBCO,
Eggenstein, Germany) containing 10% fetal bovine serum
were used to determine the T-cell proliferative response by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) staining after Aβ42 stimulation in vitro for 72 hours.
MTT-stained cells were analyzed using an enzyme-linked
immunosorbent assay (ELISA) plate reader (Magellan; Tecan
Austria, Grodig, Austria) at 450-nm absorbance. The data
are expressed in SI units, and the means are the product of
(stimulated cells – medium) ÷ (unstimulated cells –medium)
detected at 450-nm absorbance.
Measurement of Aβ42 protein-specific antibodies
The level of anti-Aβ42 serum IgG antibodies was deter-
mined by ELISA in 96-well plates coated with Aβ42 protein
at 10 μg/ml and detected with a secondary goat anti-mouse
IgG antibody conjugated with horseradish peroxidase (HRP;
Bio-Rad Laboratories, Hercules, CA, USA). Absorbance at
450 nm was measured with a Magellan ELISA plate reader.
Fibrillar Aβ deposition and histological analysis
Thioflavin S staining was used, which is common for
fluorescent staining of fibrillar amyloid deposition [39].
Brain tissue was fixed in 4% neutral buffered formalin
and mounted in paraffin blocks. After deparaffinization
and hydration, the sections were washed in PBS and
incubated in a solution containing 0.25% potassium per-
manganate and 1% oxalic acid until they appeared white.
The sections were then washed in water and stained for
3 minutes with a solution of 0.015% thioflavin S in 50%
ethanol. Finally, the sections were washed in 50% etha-
nol and in water, then dried and dipped in Histo-Clear
(National Diagnostics, Atlanta, GA, USA) histological
clearing agent before being coverslipped with Permount
(Sinopharm Chemical Reagent Co., Ltd, Shanghai, China)
mounting medium [40]. The sections were examined
using three equidistant sections per animal at 488-nm
emission. Quantification and statistical analysis of staining
were carried out using Image-Pro Plus version 6.0 soft-
ware (Media Cybernetics, Rockville, MD, USA).
Immunohistochemical staining
For Aβ plaque immunohistochemistry, brain tissue was
fixed in 4% neutral buffered formalin and mounted in par-
affin blocks. After deparaffinization and hydration, tissue
sections in citric acid buffer solution (pH 6.0, antigen re-
pair) were placed in the microwave for antigen retrieval.
Next, sections were put into 3% hydrogen peroxide solu-
tion, incubated at room temperature for 25 minutes and
placed in the PBS solution (pH 7.4) and then shaken and
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oxidase. The tissue sections were reacted first for 1 hour at
room temperature or overnight at 4°C with monoclonal
antibody anti-Aβ (1:200 dilution; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) or anti-CD4 (1:100 dilution; ABclo-
nal, Wuhan, China). All primary antibodies were diluted in
5% bovine serum albumin (BSA)/PBS buffer and incubated
with the sections before they were washed three times with
PBS and then incubated with HRP-labeled secondary anti-
body (1:200 dilution; KPL, Gaithersburg, MD, USA) for
50 minutes at room temperature. 3,3′-Diaminobenzidine
coloration (Invitrogen) was carried out, and the reaction
product was kept at room temperature without light
for 10 minutes and stained with hematoxylin and eosin
(H&E). All of the sections were detected with an EVOS
FL cell imaging system (Life Technologies, Carlsbad, CA,
USA) in visible light. Quantification and statistical ana-
lysis of staining were carried out using Image-Pro Plus
version 6.0 software (Media Cybernetics).
Microhemorrhage staining and hematoxylin and
eosin staining
For microhemorrhage staining, brain tissue taken from
14-month-old AD mice after the fifth immunization was
mounted and stained for hemosiderin using 2% potassium
ferrocyanide in 2% hydrochloric acid for 15 minutes,
followed by counterstaining in a 1% neutral red solution
for 10 minutes at room temperature. Microhemorrhage
events in the form of Prussian blue-positive profiles were
observed on all brain tissue sections from each mouse by
microscopy (Life Technologies) in visible light. For H&E
staining, the brains taken from the Aβ42 autoimmune
encephalomyelitis (Aβ42-EAE) mice on day 21 after in-
duction were fixed in 4% paraformaldehyde. Paraffin
sections were stained with H&E and observed by micros-
copy (Life Technologies) in visible light.
Plasmid expression tests
The BHK-21 cell line was used for detecting pVAX1-Aβ42
transfection and expression with Lipofectamine 2000
reagent (Invitrogen). The BHK-21 cells were put into
24-well plates at 105 per well. The plasmid was transfected
using 1 μg of plasmid and 2 μl of Lipofectamine 2000 in
500 μl of serum-free medium. Serum-free medium was
replaced after 3 hours with serum-containing medium.
The whole operation was carried out according to the
Lipofectamine 2000 kit instructions. The cells were
collected in radioimmunoprecipitation assay lysis buf-
fer (Beyotime, Shanghai, China) at 48 hours after
transfection, and the plasmid expression was tested
by Western blot analysis. The primary anti-Aβ42 anti-
body (1:1,000 dilution; Santa Cruz Biotechnology) or
glyceraldehyde 3-phosphate dehydrogenase antibody
(anti-GAPDH; Abcam, Cambridge, MA, USA) wasincubated overnight at 4°C and washed. The HRP-
labeled anti-mouse IgG secondary antibodies (1:3,000
dilution; Santa Cruz Biotechnology) were incubated
for 1 hour at room temperature and washed. The
blots were analyzed by chemiluminescence detection.
Behavioral tests
Open-field test
Behaviors of APP695 mice were measured using the
open-field test. We used EthoVision XT monitoring and
analysis software (EthoVision XT; Noldus Ltd, Wageningen,
the Netherlands) and a 50 × 50–cm open field. The open
field was divided into three areas, which included the per-
ipheral zone (zone 1) and the central zone (zones 2 and 3).
Zone 1 was 8 cm away from the edge of the open field.
Zone 3 occupied the central area, which was 16% of the
total. The remaining area was designated zone 2. Each
mouse had 5 minutes of free movement in the open field.
We recorded the length of time that each mouse stayed in
each zone and the frequency that the mouse was in the
mobile state. Mobility was the state variable and included
three different variables: immobile, mobile and highly mo-
bile. The mouse was considered to be immobile when the
change in area of the mouse between current sample and
the previous sample (referred to as the changed area)
was <20%, highly mobile when the changed area was >60%
and mobile when the changed area was between 20% and
60%. The amount of time spent in the peripheral zone is a
manifestation of thigmotaxis [41]. Room temperature was
kept constant, and the light level was even across the open
field. The open field was wiped clean with 75% alcohol and
dried before each experiment to remove residual odors.
Morris water maze
Learning and memory were tested using the Morris
water maze (MWM) 1 day after the end of the open-
field test. The protocol for the MWM test was modified
from previously reported methods [42,43]. Briefly, the
apparatus included a pool with a diameter of 100 cm
that was filled with opaque water at 20°C ± 1. An escape
platform 15 cm in diameter was placed 0.5 cm below the
water surface. Geometric objects with contrasting colors
were set at the remote ends of the water tank as reference
points. Room temperature was kept constant at 20°C ± 1,
and the light level was even throughout the room. Spatial
memory was assessed by recording the latency time for
the animal to escape from the water onto a submerged
escape platform during the learning phase. The platform
was in zone 4 and defined as zone 5. The mice were
studied in four trials per day for 3 consecutive days. The
mice were allowed to stay on the platform for 15 sec-
onds before and after each trial. The time that it took
for an animal to reach the platform (the latency period)
was recorded. Twenty-four hours after the learning phase,
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platform for sixty seconds, and the time spent in the
region was recorded. Monitoring was performed with a
video tracking system (EthoVision XT).
Detection of insoluble Aβ42 by enzyme-linked
immunosorbent assay
The brains of APP695 mice were extracted in Tris-HCl
buffer at pH 8.0 and centrifuged at 4°C and 20,000 × g
for 20 minutes. After we discarded the supernatant, we
washed the pellet in Tris-HCl pH 8.0 buffer three times
and homogenized it in buffer composed of 6 M guanidine
hydrochloride with -Tris-HCl pH 8.0. After it was son-
icated at room temperature for 30 seconds, the sample
was incubated for 1 hour at room temperature and
then centrifuged at 4°C and 20,000 × g for 20 minutes.
Samples were diluted 1:12 in ELISA bicarbonate buffer
pH 9.6, incubated in 96-well plates at 4°C overnight and
assayed with a primary anti-Aβ antibody (2B9, diluted
1:500; Santa Cruz Biotechnology) and secondary goat
anti-mouse IgG antibody conjugated with HRP (diluted
1:1,000; Bio-Rad Laboratories). Absorbance at 450 nm was
measured with an ELISA plate reader (Magellan).
Analysis of inflammatory cytokines
Brain tissue was homogenized by ultrasonication in cold
PBS after perfusion. After supernatants were centrifuged
at 8,000 rpm/min at 4°C for 30 minutes, they were diluted
1:10 with cold PBS and assayed by cytometric beads array
(CBA; BD Biosciences) so that we could detect expression
levels of IL-6, IL-1β, tumor necrosis factor α (TNF-α)
and IFN-γ.
Induction of experimental autoimmune encephalomyelitis
We used a myelin oligodendrocyte glycoprotein–induced
EAE (MOG-EAE) model. Female 8-week-old C57BL/6
mice were immunized with 200 μg/100 μl MOG 35–55
peptide fragment emulsified in 100 μl of 5× CFA (500 μg/
100 μl killed H37Ra/CFA; Sigma-Aldrich). We injected a
total of 200 μl of CFA into the animals, which was divided
between two subcutaneous posterior auricular sites. Pertus-
sis toxin (PT) (200 ng/mouse; Sigma-Aldrich) was injected
intraperitoneally on days 0 and 1 [44].
Aβ42-EAE-induced brain inflammation
To mimic the results obtained from AN-1792 vaccine-
induced brain inflammation and encephalitis [11], we
used Aβ42 protein (200 μg/100 μl) to replace MOG in
the MOG-EAE model described in the preceding sub-
section and used this Aβ42-EAE model as the positive
experimental control. After EAE induction, the mice
were immunized using various regimens via the tibialis
anterior muscle on days 0 and 14. The regimens used
were as follows: the protein group was immunized withAβ42 protein at 200 μg/mouse, the plasmid group was
immunized with pVAX1-Aβ42 at 100 μg/mouse and the
coimmunization group was immunized with a mixture of
200 μg of Aβ42 protein and 100 μg of pVAX1-Aβ42. We
used the untreated MOG-EAE or Aβ42-EAE model
mice as positive controls. On day 21, the mice were
anesthetized before heart perfusion with cold PBS. The
brain tissues were isolated and digested with trypsin
(MACGENE, Beijing, China) at 37°C for 0.5 hour to ob-
tain single-cell suspensions. The brain cells were stained
with FITC/anti-CD3 and allophycocyanin (APC)/anti-CD4
antibodies (eBioscience).
CD25− induced antigen-specific regulatory T-cell
transfer assay
Foxp3-eGFP mice were used as donor mice and were
coimmunized intramuscularly twice (with a 14-day interval)
with a mixture of 200 μg of Aβ42 protein and 100 μg of
pVAX1-Aβ42. Splenocytes were isolated from the coimmu-
nized donor mice 7 days after the second immunization,
stained with APC anti-mouse CD4+ and Foxp3+ and
PE-Cy5-labeled anti-mouse CD25+ antibodies, and sorted
using a BD FACSAria II flow cytometer. Any cells stained
for CD25+ were excluded. The sorted CD25− iTreg cells
were adoptively transferred intravenously at 106 per animal
into C57BL/6 mouse recipients that had been immunized
twice with CFA-emulsified Aβ42 protein to induce Aβ42-
EAE-induced inflammation.
On day 21, all recipients were anesthetized, and heart
perfusion was performed with cold PBS. The brains were
separated and digested with trypsin at 37°C for 0.5 hour
to obtain single-cell suspensions as described in the
preceding subsection. All cells were stained with FITC/
anti-CD3 and APC/anti-CD4 antibodies.
Statistical analysis
The results are presented as means ± SD. Except for data
derived from the MWM experiments, statistical analysis
was carried out by parametric one-way analysis of variance
(ANOVA) and t-tests were used for comparisons between
two groups. In the MWM tests, escape latency in the hid-
den platform trial was analyzed using two-way ANOVA of
repeated measures, and one-way ANOVA was conducted
to assess the data obtained from the probe trial. Differences
were considered to be statistically significant at P < 0.05.
Results
Aβ42 coimmunization induces high immunoglobulin G titer
anti-Aβ42 antibodies capable of binding to amyloid plaques
Anti-Aβ antibodies are considered to be the main contribu-
tors to the efficacy of AD vaccines [8,27]. To test whether
Aβ42 protein vaccine or Aβ42 protein plus Aβ42-coding
DNA vaccine (coimmunization according to the regimen
described in the Methods section) could elicit a robust
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nized intramuscularly at biweekly intervals. Serum samples
were taken, and ELISA was performed to measure IgG
titers. The coimmunized group had higher IgG titers than
the protein-only vaccine group (P < 0.05) (Figure 1A). The
IgG titers induced by the DNA vaccine were 2 log10 lower
than in the coimmunized group and 1 log10 lower than in
the protein vaccine group (Additional file 1: Figure S1A).
To further test the specificity of the antibodies generated in
immunized mice, sera were used to immunostain amyloid
plaques from APP/PS1 mice. The APP/PS1 mouse is a
model of AD characterized by early and massive accumula-
tion of amyloid plaques [38]. As shown in Figure 1B, serum
samples from the coimmunized group strongly reacted with
plaques in the cortex and hippocampus, similar to the posi-
tive control polyclonal anti-Aβ antibody 3552. We also used
another well-established model, the APP695 transgenicFigure 1 Coimmunization against Aβ induces high levels of anti-Aβ42
last immunization of C57BL/6 mice (A) and amyloid precursor protein APP695
by enzyme-linked immunosorbent assay (ELISA). Mean titers (n = 6) are expre
cortical tissue sections of 9-month-old APP/PS1-transgenic mice. The sections
coimmunized mice (co-Aβ42) and protein-immunized mice (pro-Aβ42). Polyc
antibody; Blue: 4′,6-diamidino-2-phenylindole. All data are presented as mean
analysis of variance, and t-tests were used to compare two groups. The resultmouse. This mouse line harbors an APP695 transgene and,
after 8 months, develops amyloid plaques and displays be-
havioral deficits in open-field tests and the MWM [36,37].
To assess whether coimmunization could also induce anti-
Aβ42 IgG in these mice, we performed ELISA to measure
the IgG titer after the fourth immunization. The result
showed that anti-sera from these coimmunized mice also
had higher IgG titers than those from protein-immunized
mice (Figure 1C). These results demonstrate that the coim-
munization strategy caused robust production of potentially
plaque-clearing anti-Aβ42 antibodies.
Coimmunization of Aβ42 reduces plaque formation in
APP695 mice
To investigate whether the coimmunization regimen could
reduce amyloid plaque formation effectively in vivo, APP695
mice were killed 14 days after the last immunization, andimmunoglobulin G. Serum samples were collected 7 days after the
mice (C), and the anti-Aβ immunoglobulin G (IgG) titer was determined
ssed in log10 units. (B) Immunofluorescent staining of hippocampal and
were stained with anti-sera from untreated mice (naïve; wild type (WT)),
lonal anti-Aβ antibody 3552 served as a positive control. Red: secondary
± SD. Statistical analysis was performed using parametric one-way
s of one of three independent experiments are shown. *P < 0.05.
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performing either ELISA against Aβ42 antigen or fibrillar
amyloid–specific thioflavin S staining. The ELISA result
shows that insoluble Aβ42 deposition in brain tissue was
significantly reduced in the coimmunized and protein-
immunized groups compared to the untreated APP695
mice (P < 0.05) (Figure 2E).
The brain cortex sections were stained with thioflavin
S, and the number of plaques as well as the total plaque
area were calculated (Figures 2C and 2D). As expected,
the APP695 model group had the highest plaque counts,
and the immunized groups had lower plaque counts,
albeit not significantly. However, the plaque areas were
significantly smaller in both the coimmunization and
protein-immunized groups than in the APP695 model
group (Figure 2B). This finding is in good agreementFigure 2 Coimmunization reduces amyloid-β deposition in brains of a
from 14-month-old Alzheimer’s disease (AD) mice (n = 5) after the fifth imm
Methods section. (A) Plaques revealed by immunohistochemistry. The sect
the primary antibody. WT, wild-type littermates used as negative controls; m
co-Aβ42, APP695 mice immunized with co-Aβ42 vaccine; pro-Aβ42, APP695
viewed under a microscope with visible light, and quantification and statis
the Image-Pro Plus version 6.0 software program. (C) Brain sections were ta
and stained with thioflavin S. (D) Cortical sections were viewed under the
statistical analysis of plaque counts and plaque area were performed using
brain tissues were used to isolate the insoluble protein fraction and analyze
antibody against Aβ. All data are presented as mean ± SD. Statistical analys
t-tests were used to compare two groups. ns, Not significant. *P < 0.05 comwith the results obtained with immunohistochemical
staining (Figures 2A and 2B). The results show that the
APP695 mice also had developed both diffused and
some focused Aβ deposits and that the immunizations
with vaccines could facilitate clearing of the plaques.
In summary, these results indicate that both the coim-
munization and protein immunization regimens effect-
ively reduced plaque loads in APP695 mice.
Coimmunization of Aβ42 attenuates abnormal
exploratory activity of APP695 mice in open-field test
The open-field test is a method of qualitatively and
quantitatively measuring general locomotor activity and
willingness to explore in rodents. The hamster prion
promoter (hPrP)-APP transgenic mouse models dis-
play a disinhibition-like phenotype in the elevated-plusmyloid precursor protein APP695 mice. Brain sections were taken
unization and stained by immunohistochemistry as indicated in the
ions were incubated with amyloid-β42 antibody (anti-Aβ42) used as
odel, amyloid precursor protein 695 (APP695) mice not immunized;
mice immunized with protein vaccine. (B) Cortical sections were
tical analysis of plaque counts and plaque area were performed using
ken from 14-month-old AD mice (n = 5) after the fifth immunization
fluorescence microscope at 488-nm emission, and quantification and
the Image-Pro Plus version 6.0 software program. (E) The remaining
d by enzyme-linked immunosorbent assay with a specific monoclonal
is was performed using parametric one-way analysis of variance, and
pared with APP695 mice.
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open field [45-47], which we confirmed for APP695
mice compared to wild-type (WT) mice (Figure 3A).
Compared with WT mice, the APP695 AD mice spent
more time in the central zone (zone 2 and zone 3) and
less time in the peripheral zone of the field (Figure 3A)
and showed an increased frequency of total mobility
(P < 0.05) (Figure 3B). The behavior of the coimmunized
and Aβ42 protein–immunized mice resembled that of their
WT littermates, with more time spent in the periphery and
less in the center. Likewise, the frequency of total mobility
was significantly decreased compared with the untreated
AD mice (Figures 3A and 3B). The DNA-immunized
group also showed some improvements, but the differ-
ences were not significant compared with those in theFigure 3 Coimmunization improves behavior of amyloid precursor pr
of amyloid precursor protein 695 (APP695) mice (n = 9) were treated with t
(that is, wild type (WT)) that did not receive any treatment were used as co
disease (AD) model controls. (A) Thigmotaxis was assessed on the basis of
regard to autonomous behaviors in the open-field test. (B) Graph showing
test. (C) Graph of the learning and memory abilities demonstrated in the M
hidden platform tests. (D) After withdrawal of the platform on the fourth d
was determined. All data are presented as mean ± SD. For the Morris wate
by two-way analysis of variance (ANOVA) of repeated measurements. One-
used t-tests to compare two groups. *P < 0.05 and **P < 0.01 compared w
co-amyloid-β42 vaccine; pro-Aβ42, APP695 mice immunized with amyloid-βcoimmunized and Aβ42 protein–immunized groups
(data was not shown).
Coimmunization of Aβ42 improves the learning and
memory of APP695 mice in Morris water maze tests
To assess spatial learning and memory function, all ani-
mals underwent MWM tests 14 days after their last
immunization. As shown in Figure 3C, there was a sig-
nificant difference overall in escape latency between the
four groups (group effect: F(4,36) = 11.13, P < 0.01;
training day effect: F(4,144) = 12.45, P < 0.01; and group ×
training day interaction: F(12,144) = 1.087, P > 0.05). The
latency to find the submerged platform decreased every
day in each group, but the escape latency in the untreated
APP695 mice was significantly longer than that of the WTotein 695 mice in open-field and Morris water maze tests. Groups
he indicated vaccines. Age- and sex-matched nontransgenic littermates
ntrols. APP695 mice without vaccination were used as the Alzheimer’s
the amount of time spent in the peripheral and central zones with
the frequency of exhibition of total mobile changes in the open-field
orris water maze. Plotted is the escape latency during 3 days of
ay, the time spent in the original underwater platform zones 4 and 5
r maze tests, escape latency in the hidden platform trial was assessed
way ANOVA was used for the data obtained from the probe trial. We
ith AD model mice. co-Aβ42, APP695 mice immunized with
42 protein vaccine.
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AD mice showed significantly decreased escape latencies
compared with those of the untreated APP695 controls
(P < 0.05), almost down to WT levels. The DNA-immunized
mice also improved their learning behavior, but not sig-
nificantly compared to the coimmunization and Aβ42
protein-immunized groups (data not shown).
In a probe test, the frequency of crossing the platform
was measured for 60 seconds on the fourth day after the
last acquisition test. As shown in Figure 3D, there was
an overall significant difference in the frequency of cross-
ing the platform between the five groups (F(4,36) = 10.45,
P < 0.01). The latency was decreased in the untreated
APP695 mice compared with the WT mice (P < 0.01).
Duration times in the platform zone were significantly
increased (P < 0.01) among both the coimmunized and
protein-immunized groups compared with the untreated
APP695 mice, whereas the DNA-immunized group showed
no improvements compared with the AD mice (P > 0.05)
(data not shown). Taken together, these results show that
that Aβ42 protein immunization as well as coimmuniza-
tion efficiently ameliorated cognitive deficits in AD mice.
Coimmunization affects inflammatory cytokines in
brain tissue
Inflammatory cytokines in brain tissue are believed to
induce brain inflammation and, in severe cases, menin-
goencephalitis. To compare the level of cytokines in the
brain tissue of the immunized and control groups, brain
tissue was homogenized and assayed for cytokine ex-
pressions by CBA (Figure 4). The results show that there
was an elevated basal inflammatory state in the brain of
APP695 mice compared to WT mice, which is indicated
by increased expression of IFN-γ, TNF-α, IL-1β and IL-6.
Aβ42 protein vaccination induced further increases in
IFN-γ and TNF-α levels compared to those of untreated
APP695 mice. In contrast, in the coimmunization group,
cytokine levels were similar to those of untreated APP695
mice (TNF-α) or even lower (IFN-γ, IL-1β and IL-6)
(Figure 4). These results suggest that the coimmuniza-
tion strategy could induce anti-inflammatory effects
in vivo by downregulating the expression of IFN-γ and
TNF-α. We checked whether CD4+ T cells had infil-
trated into brain tissues. Immunohistochemistry revealed
that there were small numbers of CD4+ T cells in the
brains of the protein-vaccinated group, indicating that
the source of increased inflammation was infiltrated T
cells (Additional file 2: Figure S3).
Coimmunization suppresses T-cell proliferation by inducing
CD25− iTreg cells
We previously demonstrated that coimmunization induced
high titers of IgG against protein antigen. Coimmunization
also induced antigen-specific iTreg cells to suppressCD4 T-cell responses in an antigen-specific manner
[33]. To test whether this would also hold true for
anti-Aβ42 coimmunization, we performed a T-cell pro-
liferation assay 7 days after the fifth immunization
(after the behavior tests had been completed). As expected,
Aβ42 protein immunization induced a twofold stimulation
compared to immunized control mice, whereas coimmuni-
zation did not induce any T-cell proliferation (Figure 5A).
The suppression of T-cell responses was apparently as-
sociated with increases in CD25− iTreg cell levels in the
coimmunized mice (Figure 5B) in a dose-dependent man-
ner (Additional file 1: Figure S1).
We next tested whether the iTreg cells affected T-cell
production of inflammatory cytokines. After immunization,
CD4+ T cells were isolated, and intracellular staining was
performed. As shown in Figure 5C, the level of IFN-γ was
downregulated, but levels of Foxp3, IL-10 and TGF-β were
upregulated, by the coimmunization regimen compared
to the Aβ42 protein–immunized group. In contrast, no
effect on the level of IL-4 was observed (Figure 5C).
These results suggest that the coimmunization protocol
induced a Th1-suppressive response, but did not affect
the humoral response.
Coimmunization prevents induced experimental
autoimmune encephalomyelitis
Because vaccinations may cause brain inflammation that
leads to meningoencephalitis, minimizing the risk of such
inflammation and meningoencephalitis has to be a major
goal in the development of an AD vaccine. EAE repre-
sents an excellent model for studying T-cell-mediated
autoimmune disease in the brain and mimics Aβ42
vaccine–induced meningoencephalitis [48]. To test the
efficacy of the coimmunization strategy in preventing
EAE, we first established an EAE animal model by
immunizing mice on day 0 with either MOG35–55
peptide + CFA + PT (MOG-EAE model) or with Aβ42
protein + CFA + PT (Aβ42-EAE model) and then with
PT on day 1. We found that the pVAX1-Aβ42 plasmid
was expressed by day 2 after transfection (Additional
file 3: Figure S4). The coimmunization vaccine can induce
the signaling pathway in dendritic cells at this time point
[34,49], and the DNA plasmid vaccine can induce T-cell
responses from day 3 after immunization [50]. Therefore,
the EAE-induced mice were further coimmunized or
protein-immunized on days 2 and 14. A schematic of
the strategy is depicted in Figure 6A. T cells infiltrating
the brain were isolated and analyzed by flow cytometry
on day 21 after the single-cell suspensions were stained
with anti-CD3 and anti-CD4 antibodies (Figure 6C). A
large number of CD3+ and CD4+ T cells had infiltrated
into the brains of MOG-induced or Aβ42-induced EAE
mice, possibly causing meningoencephalitis. Even larger
brain infiltrations were observed in the Aβ42-induced
Figure 4 Coimmunization suppressed the expression of inflammatory cytokines in the brains of amyloid precursor protein 695 transgenic
mice. Protein lysates were prepared from the brains of wild-type (WT), amyloid protein precursor 695 (APP695) and vaccinated mice 7 days after the
fifth immunization (n = 5). The expression of cytokines was determined by cytometric bead array. Levels of interferon γ (IFN-γ), tumor necrosis factor α
(TNF-α), interleukin 1β (IL-1β) and IL-6 were analyzed, and mean ± SD values are expressed as picograms per 100 milligrams of brain tissue. Statistical
analysis was performed using parametric one-way analysis of variance, and t-tests were used to compare two groups. *P < 0.05 compared with APP695
mice. co-Aβ42, APP695 mice immunized with co-amyloid-β42 vaccine; pro-Aβ42, APP695 mice immunized with amyloid-β42 protein vaccine.
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(Figures 6C and 6D). However, in sharp contrast, the num-
ber of T cells was dramatically reduced to the level in the
naïve group when the mice were coimmunized (P < 0.0001)
(Figures 6C and 6D). These results were confirmed in histo-
pathological analysis of H&E-stained brain sections. MOG-
EAE and Aβ42-EAE caused large clusters of infiltrated T
cells (Figure 6E), whereas no T-cell infiltration was detected
in the coimmunized animals, thus resembling the situation
in naïve mice (Figure 6E). This finding result demonstrates
that coimmunization with Aβ42 DNA and Aβ42 protein in-
duced a protective response against brain inflammation.
Coimmunization-induced regulatory T cells suppressed
brain inflammation
We wanted to examine whether the iTreg cells acted as
the main suppressors of Aβ42 antigen-specific T cells.To this end, we isolated iTreg cells from coimmunized
Foxp3-eGFP mice and adoptively transferred them into
Aβ42-induced EAE model animals as recipients on
days 5 and 12 after EAE induction (Figure 7A). As a
control, näive regulatory T cells (nTregs) were trans-
ferred. T cells isolated from each brain were analyzed
by FACS (Figure 7B), and the sum of results is pre-
sented as a bar graph in Figure 7C. On average, more
than 100 T cells per 106 brain cells infiltrated brains of
MOG-induced EAE mice, and about 70 T cells per 106
brain cells infiltrated Aβ42-induced EAE mice. Trans-
ferring nTregs had no impact on T-cell infiltration,
but transfer of iTregs significantly reduced T-cell infiltra-
tion in the brains of Aβ42-induced EAE mice (P < 0.001)
(Figure 7C). This result demonstrates that the iTreg cells
induced by coimmunization did indeed suppress Teff cell
infiltration into the brain.
Figure 5 Coimmunization suppresses T-cell proliferation by inducing CD25− antigen-specific regulatory T cells. Splenocytes were isolated
from vaccinated and control mice 7 days after the fifth immunization and used for intracellular staining or for proliferation assays (n = 6).
(A) Frequency of FoxP3+ cells in the total CD4+ T cells after the coimmunization compared with other groups by performing fluorescence-
activated cell sorting analysis (FACS) analysis. (B) The level of T-cell proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay. The splenocytes were restimulated for 3 days in vitro using amyloid-β42 (Aβ42) protein as a specific antigen, bovine serum
albumin (BSA) as a nonspecific antigen or anti-CD3 as a positive control. We added anti-CD28 antibody to all T cells as a costimulant. The cell
proliferation rate is expressed as the stimulation index (SI). (C) Splenocytes were restimulated for 12 hours in vitro using Aβ42 protein as a specific
antigen and blocked with brefeldin A for 8 hours. The lymphocytes were first gated on CD4+ T cells and then used for intracellular staining to
detect transforming growth factor β (TGF-β) and interleukin 10 (IL-10), IL-4 and interferon γ (IFN-γ) followed by FACS analysis. A result typical
of three independent experiments is shown. All data are presented as mean ± SD. Statistical analysis was performed using parametric one-way
analysis of variance, and t-tests were used to compare two groups. *P < 0.05, **P < 0.01 compared with protein-vaccinated model mice. co-Aβ42,
APP695 mice immunized with co-amyloid-β42 vaccine; ns, Not significant; pro-Aβ42, APP695 mice immunized with amyloid-β42 protein vaccine; WT,
Wild type.
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mens with Aβ42 protein and Aβ42 coding DNA-induced
iTregs strongly reduced brain inflammation and infiltra-
tion of T cells into the brain. At the same time, a robust
anti-Aβ42 antibody response was elicited that effectively
reduced plaque formation. Therefore, coimmunization is
an attractive and novel strategy for use in AD vaccine
development.
Discussion
In this study, the co-immunization strategy that we de-
veloped was applied for the first time in an AD mouse
model. Our goal in mixing the Aβ42 protein and Aβ42
DNA vaccine was to achieve high levels of anti-Aβ42
antibodies with concurrent inhibition of T-cell-mediated
inflammation. This should ameliorate cognitive deficitswhile lowering the adverse effects of neuroinflammation
in conventionally vaccinated mice and humans. We dem-
onstrate that the coimmunization of DNA encoding Aβ42
plus Aβ42 protein in APP695 mice indeed induced higher
levels of IgG against Aβ, resulting in reduction of Aβ load
and dramatically improved behavior in Morris water maze
and open-field tests. The coimmunization induced
high levels of iTreg with a strong ability to suppress
CD4+ T-mediated inflammation. This resulted not only
in suppression of T-cell proliferation but also, import-
antly, in reduced expression of inflammatory cyto-
kines, including IFN-γ, IL-1β, IL-6 and TNF-α in brain
tissue samples. We found small numbers of CD4+ T
cells in the brains taken from the protein vaccine group
(Additional file 2: Figure S3). So we speculated that the
source of increased inflammatory stimuli, such as IFN-γ
Figure 6 (See legend on next page.)
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Figure 6 Coimmunization prevents autoimmune encephalomyelitis induced by amyloid-β42 protein. (A) Schematic representation of
amyloid-β42 autoimmune encephalomyelitis (Aβ42-EAE) induction and vaccination. EAE was induced by immunization with Aβ42 protein + complete
Freund’s adjuvant (CFA) + pertussis toxin (PT) (Aβ42-EAE model) on day 0, and then, on day 1, PT was injected a second time. The EAE-induced mice
were further coimmunized or protein-immunized on days 2 and 14. T cells infiltrating the brain were assessed by isolating T cells from the brain on
day 21. (B) Single-cell suspensions of brain cells taken from EAE-induced animals were isolated with or without vaccination or from naïve
C57BL/6 mice and then stained on day 21. FSC, Forward scatter; SSC, Side scatter. (C) The cells were immunostained for CD3 and CD4 and
analyzed by fluorescence-activated cell sorting (FACS). The upper left panel shows cells from naïve mice with no antibody staining, followed
by antibody-stained cells from the naïve mice, from the myelin oligodendrocyte glycoprotein (MOG)–induced EAE (MOG-EAE) model, from
the Aβ42-induced EAE model, from the Aβ42-induced EAE mice vaccinated with Aβ42 protein vaccine or from the coimmunized mice.
(D) Graph showing the number of CD4+ T cells in brain. The number of double-positive CD3+ and CD4+ T cells per 106 brain cells from the
groups of six animals represented in (C) were statistically analyzed and plotted. (E) Histopothological examination of brain cortex on the
sixth day after EAE model induction, stained with hematoxylin and eosin. The naïve tissue section was taken from naïve mice without any
treatment or induction. The results shown are representative of three independent experiments. Statistical analysis was performed using
parametric one-way analysis of variance, and t-tests were used to compare two groups. The arrows point to the lymphocytes areas. The bars
represent 50 micrometer in length. co, Coimmunization; pro, Protein immunization. All data are presented as mean ± SD. ****P < 0.0001
compared with protein-vaccinated Aβ42-EAE mice.
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cytokines is thought to lead to T cell infiltration and is
associated with in situ lesions [5,51,52]. We also looked
for microhemorrhaging in the brain tissue by applying
Prussian blue staining and found that this coimmuni-
zation vaccine did not induce microhemorrhagingFigure 7 Effects of induced antigen-specific regulatory T cell transfer on
autoimmune encephalomyelitis model. CD4+CD25−Foxp3+ induced antige
Foxp3 enhanced green fluorescent protein (Foxp3-eGFP) mice on day 7 a
amyloid-42β-induced autoimmune encephalomyelitis (Aβ42-EAE) model mice
iTreg cell transfer to prevent Aβ42-EAE. iTregs were isolated from Foxp3-eGFP
Aβ42-EAE model mice on days 5 and 12 after the model was induced. CD4+C
Freund’s adjuvant; nTreg, näive regulatory T cell; PT, Pertussis toxin. (B) Single
or without vaccinations, or from naïve C57BL/6 mice, and stained on day 21.
fluorescence-activated cell sorting. MOG, Myelin oligodendrocyte glycoprotein
cells taken from the groups of six animals detected the same way as in (B) w
three independent experiments. All data are presented as mean ± SD. Statisti
and t-tests were used to compare two groups. ***P < 0.001 compared with A(Additional file 4: Figure S2). We did find one mouse
in the protein-immunized group that had a Prussian
blue–positive spot, but we could not find cerebral amyloid
angiopathy (CAA) when we applied Congo red staining in
both immunized groups up to 10 months after their initial
immunization, suggesting that these animals may notT-cell infiltration in the brain tissue in the amyloid-β42-induced
n-specific regulatory T cells (iTregs) were isolated from coimmunized
fter the second coimmunization and adoptively transferred into
on days 5 and 12 after EAE induction. (A) Schematic representation of
mice after the second coimmunization and adoptively transferred into
D25+Foxp3+nTreg transfers were used as a control. CFA, Complete
-cell suspensions of brains were isolated from EAE-induced animals with
The cells were immunostained for CD3 and CD4 and analyzed by
. (C) The number of double-positive CD3+ and CD4+ T cells per 106 brain
ere statistically analyzed and plotted. The results shown are typical of
cal analysis was performed using parametric one-way analysis of variance,
β42-EAE mice.
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future studies in older mice are warranted to investi-
gate this problem.
The protein Aβ42 that we have used in this study has
one main difference from AN-1792, the vaccine used in
a phase II trial conducted with human patients [10]. We
used CFA and IFA as adjuvants in our protein vaccine,
whereas QS-21 was the adjuvant used in AN-1792 [11].
Both adjuvants not only augment antibody responses
but also elicit strong helper T-cell responses, producing
cytokines such as IFN-γ [53-58], which can cause perive-
nular inflammatory encephalomyelitis during vaccination
[5]. In earlier animal experiments, however, CFA and
IFA were demonstrated to improve the efficiency of
Aβ42 antibody production to attenuate AD-like pathology
in the PDAPP mouse [8].
Our data show that the efficacy of the coimmuniza-
tion vaccine to reduce plaque load is comparable to a
“conventional”, well-established protein vaccine, but
at the same time is superior because it causes less side
effects.
The main concern with regard to current protein-based
Aβ42 AD vaccines is that they can cause meningoencephal-
itis in AD patients, because vaccination with Aβ42-based
vaccines might induce T-cell activation and infiltration into
the central nervous system [10]. To avoid this problem, sev-
eral alternative approaches are currently being developed,
including the use of monoclonal antibody against Aβ42 for
passive immunization or a truncated form of Aβ42 as a vac-
cine, such as Aβ1−15-DT conjugate, which could increase
antibody titers by adding nonrelevant epitopes of a DT
carrier for T helper cells [14]. Researchers who have used
these approaches have demonstrated that Aβ deposits in
AD mouse models were effectively cleared, and several of
these approaches were subsequently tested in clinical set-
tings [28,59-61]. The aim of all of these approaches is to
prevent the activation of CD4+ T-cell responses caused by
the T-cell epitope located in the Aβ15-42 fragment. How-
ever, to date, no published clinical trial data or other evi-
dence has shown that these approaches can be used to
develop an effective vaccine against AD and prevent en-
cephalitis or other adverse effects.
iTreg cells regulate T-cell-mediated immune reactions,
thereby controlling autonomous immune responses. The
use of Treg cells to treat inflammatory reactions has been
considered a promising strategy, particularly against auto-
immune diseases, allergies and asthma [62-65]. Although
researchers have demonstrated powerful suppressive
effects of iTreg against Teff cells in numerous studies,
no strategy designed to develop an AD vaccine using
iTregs to prevent T-cell-mediated brain inflammation
has been tested. In our present study, we show for the
first time that coimmunization of Aβ42 can indeed in-
hibit T cells by inducing iTreg cells in normal C57BL/6mice (Additional file 1: Figure S1) and in APP695 mice
(Figure 5).
To establish a link between iTreg cells and reduction of
T-cell-mediated inflammation, we used an Aβ42-induced
EAE model. The aim was to mimic the CD4+ T-cell in-
filtration into the brain that was observed with the use
of AN-1792. We observed that this coimmunization
significantly inhibited the formation of encephalitis by
inducing a group of iTregs to inhibit the migration of
CD4+ T cells into the brain. To conclusively demon-
strate that the iTreg cells induced by coimmunization
suppressed T-cell-mediated infiltration and inflamma-
tion in brain tissue, we adoptively transferred iTreg
cells obtained from a donor mouse that had been
coimmunized by the regimens into EAE-induced mice
with inflammatory brain tissues. The results show that
iTreg cells could indeed inhibit inflammatory CD4+ T-cell
infiltration and thus reduce the number of T cells in
brain tissue. Altogether, these results demonstrate that
coimmunization inhibited the inflammatory response
that was induced by the protein vaccine and that the
inhibition was produced by induction of high levels of
iTregs. The iTregs strongly suppressed CD4+ T-cell
proliferation, inflammatory cytokine expression and migra-
tion into the inflammation site.
Conclusions
The data derived from our study of the APP695 mice de-
scribed in this article demonstrate that the coimmuniza-
tion regimens with Aβ42 protein and Aβ42-coding DNA
induced both high titers of antibody against Aβ42, which
effectively reduced plaque formation in this AD mouse
model, and induced iTregs that strongly reduced brain
inflammation and infiltration of T cells into the brain.
AD development was ameliorated. Therefore, the results
are a proof of concept and indicate that the coimmuniza-
tion strategy reported herein should be further developed
with the goal of testing it in human patients.
Additional files
Additional file 1: Figure S1. Effects of coimmunization on immune
responses. Groups of C57BL/6 mice (n = 6) were immunized by
coimmunization with protein/DNA at various ratios (100 μg/100 μg, 100
μg/200 μg, 100 μg/300 μg and 200 μg/100 μg), protein vaccine alone or
DNA vaccine alone, or they were un-vaccinated as controls. (A) Total
anti-Aβ IgG was analyzed by ELISA on day 7 after the third immunization.
Mean titers are expressed as log10 values. (B) Splenocytes were isolated
from each group on day 7 after the third immunization and stimulated
for 3 days in vitro using Aβ42 protein as the specific antigen, BSA as a
nonspecific antigen or anti-CD3 as a positive control stimulant. All of the
T cells were given anti-CD28 as a costimulant. The level of T-cell proliferation
was evaluated by MTT assay, and the data are expressed as a stimulation
index. (C) The number of CD4+CD25−Foxp3+ iTreg cells as a percentage of
total CD4+ T cells was analyzed by FACS analysis. Data shown are the results
of three independent experiments. All data are presented as mean ± SD.
Statistical analysis was performed using parametric one-way ANOVA, and
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with Aβ42 protein vaccinated mice.
Additional file 2: Figure S3. CD4+ cells staining of brain sections from
AD model mice after immunization. Brain sections were taken from
14-month-old AD mice (n = 5) after the fifth immunization and stained
for immunohistochemistry analysis. The sections were incubated with
anti-CD4 as primary antibody. WT refers to littermate negative controls,
and the model used was APP695 mice without immunization. Co-Aβ42
refers to APP695 mice immunized with co-Aβ42 vaccine, and pro-Aβ42
refers to APP695 mice immunized with protein vaccine. Cortical sections
were viewed under a microscope with visible light.
Additional file 3: Figure S4. Expression of pVAX1-Aβ42 plasmid
transfected into BHK-21 cells. The pVAX1-Aβ42 plasmid was transfected
into BHK-21 cells with Lipofectamine 2000 reagent. The cells were collected
at 48 hours after transfection. The expression of the plasmid was detected
by Western blot analysis, a commercially purchased Aβ42 peptide was used
as a positive control and BHK-21 cells without transfection were used as a
negative control. The positive Aβ42 peptide was about 4 kDa, and GAPDH
was about 30 to 40 kDa. Data shown in each panel are derived from one of
two independent experiments with similar results.
Additional file 4: Figure S2. Prussian blue staining of brain sections
from AD model mice after immunization. For microhemorrhage staining,
brain sections from 14-month-old AD model mice (n = 5) after the fifth
immunization were fixed and stained using the Prussian blue method.
WT means littermate negative controls, model was APP695 mice without
immunization. Co-Aβ42 refers to the APP695 mice immunized with co-Aβ42
vaccine, and pro-Aβ42 refers to the APP695 mice immunized with protein
vaccine. Cortical sections were viewed under a microscope with visible light.
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